Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection?

被引:31
作者
Jeng, KS
Sheen, IS
Tsai, YC
机构
[1] Chang Gung Mem Hosp, Liver Res Unit, Taipei 10591, Taiwan
[2] Mackay Mem Hosp, Dept Surg, Taipei, Taiwan
关键词
D O I
10.1111/j.1572-0241.2004.30227.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Alpha-fetoprotein messenger RNA (AFP mRNA) in the peripheral blood (PB) of patients with hepatocellular carcinoma (HCC) has been considered to represent isolated tumor cells. We investigated its association with the prognosis after curative resection. METHODS: Using a reverse-transcription polymerase chain reaction (RT-PCR)-based assay, AFP mRNA in the PB was determined prospectively in control and in 81 patients with curative resection for HCC. RESULTS: Twenty-two (27.2%) and 19 (23.4%) of 81 HCC patients had AFP mRNA in their pre- and postoperative PB. Its presence preoperatively was not associated with an increased risk of HCC recurrence (54.5% vs 40.7%, p = 0.264). In contrast, the postoperative presence associated significantly with a higher incidence of recurrence (89.5% vs 30.6%, p < 0.001), irrespective of preoperative status. The odds ratio for HCC recurrence was 19.2 (95% confidence interval [CI]: 4.0-91.7). The cumulative probability of recurrence-free survival was also much lower in patients with postoperatively positive AFP mRNA (p < 0.001). The Cox proportional hazards model also demonstrated a significant association with recurrence (p = 0.002). Preoperative serum AFP is also a significant factor and combination with postoperative AFP mRNA enhances the predictability, sensitivity (75.0%), specificity (93.3%), positive prediction (90.0%), and negative prediction (82.4%). CONCLUSIONS: The postoperative detection of AFP mRNA in PB is associated with an increased risk of earlier HCC recurrence. Combination with preoperative serum AFP is useful in predictability.
引用
收藏
页码:1503 / 1509
页数:7
相关论文
共 41 条
[1]
[Anonymous], 1997, AJCC CANC STAGING MA
[2]
Liver transplantation for hepatocellular carcinoma [J].
Bismuth, H ;
Majno, PE ;
Adam, R .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :311-322
[3]
CHEN MF, 1994, ARCH SURG-CHICAGO, V129, P738
[4]
Recurrent hepatocellular carcinoma after liver transplantation: Spectrum of CT findings and recurrence patterns [J].
Ferris, JV ;
Baron, RL ;
Marsh, JW ;
Oliver, JH ;
Carr, BI ;
Dodd, GD .
RADIOLOGY, 1996, 198 (01) :233-238
[5]
THE BIOLOGY OF HUMAN CANCER METASTASIS [J].
FIDLER, IJ .
ACTA ONCOLOGICA, 1991, 30 (06) :669-675
[6]
Hematogenous spreading of hepatocellular carcinoma cells: Possible participation in recurrence in the liver [J].
Funaki, NO ;
Tanaka, J ;
Seto, SI ;
Kasamatsu, T ;
Kaido, T ;
Imamura, M .
HEPATOLOGY, 1997, 25 (03) :564-568
[9]
GOLDBLATT SA, 1965, ACTA CYTOL, V9, P6
[10]
Greene FL., 2002, AJCC CANC STAGING HD, V6th